Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13875779 | 0.88 | HDAC1 (0.47) | SMN1; SMN2HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL8764157 | 0.88 | KAT2B (0.46) | SMN1; SMN2CTSLCTSBCTSKCASP3 | |
| SCHEMBL3616171 | 0.86 | HDAC1 (0.50) | SMN1; SMN2HDAC1HDAC8HDAC6GAA | |
| SCHEMBL6199732 | 0.84 | CASP3 (0.60) | CTSLCTSBCTSKCASP3TACR2 | |
| SCHEMBL949589 | 0.82 | CTSK (0.43) | SMN1; SMN2CTSLCTSBCTSKALDH1A1 | |
| SCHEMBL949590 | 0.82 | CTSK (0.43) | SMN1; SMN2CTSLCTSBCTSKALDH1A1 | |
| SCHEMBL13637760 | 0.82 | CASP1 (0.55) | CTSLCTSBCASP3 | |
| SCHEMBL8641646 | 0.81 | CTSL (0.46) | CTSLCTSBCTSKCASP3NAAA | |
| SCHEMBL8641654 | 0.81 | CTSL (0.46) | CTSLCTSBCTSKCASP3NAAA | |
| SCHEMBL12450523 | 0.80 | CASP1 (0.47) | SMN1; SMN2CTSLCTSBCTSKCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK SHARP & DOHME CORP. | 2010-01-14 | — | — | US | disclosed |
| WO-2008039420-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, SI, MGAM2 | SMN1; SMN2 3397/4885CTSL 91/4885CTSB 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.